“Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs” – a collaborative effort between the International Neuroendocrine Cancer Alliance (INCA) and Novartis, was published in the Journal of Global Oncology.
The Global NET Patient Survey is the first large, global initiative that attempts to characterize the impact of NETs from the patient perspective.
Impact of survey data
Despite the considerable impact of neuroendocrine tumors (NETs) on patients’ daily lives, the journey of the patient with a NET has rarely been documented, with published data to date being limited to small qualitative studies. NETs are a complex group of tumours that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. NETs are difficult to diagnose as the symptoms may be vague and attributed to more common problems such as irritable bowel syndrome (IBS), Crohn’s disease, peptic ulcer disease, gastritis, asthma, blood glucose problems, menopause and blood pressure problems.